Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PRE 
Prenetics Global Ltd (PRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: PRE (2-star) is a SELL. SELL since 2 days. Simulated Profits (52.15%). Updated daily EoD!
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $26
1 Year Target Price $26
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 44.81% | Avg. Invested days 29 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 249.40M USD | Price to earnings Ratio - | 1Y Target Price 26 |
Price to earnings Ratio - | 1Y Target Price 26 | ||
Volume (30-day avg) 1 | Beta 0.33 | 52 Weeks Range 3.09 - 17.99 | Updated Date 11/2/2025 |
52 Weeks Range 3.09 - 17.99 | Updated Date 11/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -87.32% | Operating Margin (TTM) -51.36% |
Management Effectiveness
Return on Assets (TTM) -15.4% | Return on Equity (TTM) -31.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 171154753 | Price to Sales(TTM) 4.37 |
Enterprise Value 171154753 | Price to Sales(TTM) 4.37 | ||
Enterprise Value to Revenue 3 | Enterprise Value to EBITDA 0.14 | Shares Outstanding 15247465 | Shares Floating 9672600 |
Shares Outstanding 15247465 | Shares Floating 9672600 | ||
Percent Insiders 18.18 | Percent Institutions 9.26 |
Upturn AI SWOT
Prenetics Global Ltd
Company Overview
History and Background
Prenetics Global Ltd is a genetic testing and digital health company founded to make personalized preventative health easier to access. They are focused on providing actionable insights and preventative solutions.
Core Business Areas
- Genetic Testing: Offers a range of genetic tests covering areas such as cancer risk, cardiovascular health, and pharmacogenomics. Focus is on personalized and preventative measures.
- Early Cancer Detection: Developing non-invasive blood-based tests for early cancer detection. Uses advanced DNA sequencing and data analysis.
- Digital Health: Provides digital health solutions, including telehealth consultations and personalized wellness programs based on genetic insights.
Leadership and Structure
The leadership team consists of experienced professionals in genetics, healthcare, and technology. The organizational structure includes departments for R&D, marketing, sales, and operations.
Top Products and Market Share
Key Offerings
- CircleDNA: CircleDNA is a consumer DNA testing kit providing insights into various aspects of health and ancestry. Competitors include 23andMe and AncestryDNA. Revenue data is not publicly available.
- ColoClear by Circle: Non-invasive stool DNA test for early detection of colorectal cancer. Competitors include Exact Sciences' Cologuard. Revenue data is not publicly available.
- iGenes: A comprehensive genetic test designed for precision medicine. Competitors are similar to other genetic testing services such as Myriad Genetics. Revenue data is not publicly available.
Market Dynamics
Industry Overview
The genetic testing and digital health market is experiencing substantial growth due to increasing awareness of personalized medicine and preventative care. There is also an increase in early detection of diseases.
Positioning
Prenetics Global Ltd aims to be a leading provider of comprehensive genetic testing and digital health solutions, with a focus on Asia and beyond. Competitive advantages include their broad range of tests and technology platform.
Total Addressable Market (TAM)
The global genetic testing market is projected to reach hundreds of billions of dollars. Prenetics Global Ltd aims to capture a significant share of this TAM through product expansion and market penetration.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio
- Strong brand recognition in some Asian markets
- Proprietary technology platform
- Experienced management team
Weaknesses
- Limited market presence in North America and Europe
- High marketing costs
- Dependence on regulatory approvals
- Limited information on financials since de-listing in 2024
Opportunities
- Expansion into new geographic markets
- Development of new genetic tests and digital health solutions
- Strategic partnerships with healthcare providers
- Increased adoption of personalized medicine
Threats
- Competition from established genetic testing companies
- Changes in regulatory landscape
- Data privacy and security concerns
- Economic downturn
Competitors and Market Share
Key Competitors
- 23andMe (DNA)
- Exact Sciences (EXAS)
- Myriad Genetics (MYGN)
Competitive Landscape
Prenetics faces competition from established players with larger market share. However, its focus on Asia and comprehensive product portfolio provide some advantages. The accuracy of this data could be affected given the de-listing of Prenetics Global Ltd.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by increased demand for genetic testing and digital health solutions in Asia. Prenetics Global Ltd had significant growth prior to delisting.
Future Projections: Future growth projections depend on the company's ability to expand into new markets, launch new products, and manage regulatory hurdles. No future projections available since de-listing.
Recent Initiatives: Recent initiatives include expanding lab facilities, launching new genetic tests, and forming partnerships with healthcare providers. Financial data is not readily available due to the limited information available since de-listing in 2024.
Summary
Prenetics Global Ltd shows promise with its innovative product line and strategic positioning in the growing genetic testing market. Its strengths lie in its diverse portfolio and focus on Asia, while weaknesses include limited market presence in certain regions and high marketing costs. Capitalizing on opportunities through expansion and strategic partnerships will be crucial to address competitive threats and ensure sustainable growth, particularly considering its recent delisting.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- Third-party market research reports
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Financial data is limited and this may affect the accuracy of the analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prenetics Global Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-05-18 | Co-Founder, Chairperson & CEO Mr. Sheng Wu Yeung | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 285 | Website https://www.prenetics.com |
Full time employees 285 | Website https://www.prenetics.com | ||
Prenetics Global Limited, a health sciences company, focuses on advancing consumer health in Hong Kong, the United States, and internationally. It sells health and wellness products under the IM8 brand name; and provides fulfillment and distribution services for sports nutrition products under the Europa brand. The company is also involved in the operation of CircleDNA, a consumer genetic testing brand that uses next-generation sequencing (NGS) technology to provide comprehensive insights into health, wellness, and genetic predispositions. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.